Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | CD200 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
|
Chemical and physical data | |
Formula | C6542H10086N1702O2102S46 |
Molar mass | 147687.22 g·mol−1 |
NY (what is this?) (verify) |
Samalizumab is a humanized monoclonal antibody designed for oncology indications.[1] Samalizumab is a recombinant humanized monoclonal antibody that targets the immunoregulatory protein CD200. Results from a Phase I study indicated the drug has potential for use in treating cancers including chronic lymphocytic leukemia. [2]
Samalizumab was developed by Alexion Pharmaceuticals.
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |